IL297114A - Preparations that include 15-hepe for the treatment or prevention of hematological disorders, and/or related diseases - Google Patents

Info

Publication number

IL297114A

IL297114A IL297114A IL29711422A IL297114A IL 297114 A IL297114 A IL 297114A IL 297114 A IL297114 A IL 297114A IL 29711422 A IL29711422 A IL 29711422A IL 297114 A IL297114 A IL 297114A

Authority

IL

Israel

Prior art keywords

hepe

subject

composition

baseline

increase

Prior art date

2020-04-03

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000203 mixture Substances 0.000 title claims description 264
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 82
• 208000014951 hematologic disease Diseases 0.000 title claims description 42
• 208000019838 Blood disease Diseases 0.000 title claims description 36
• 201000010099 disease Diseases 0.000 title description 29
• 238000000034 method Methods 0.000 claims description 343
• 210000003743 erythrocyte Anatomy 0.000 claims description 88
• 230000007423 decrease Effects 0.000 claims description 70
• 208000035475 disorder Diseases 0.000 claims description 53
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 52
• 239000000194 fatty acid Substances 0.000 claims description 52
• 229930195729 fatty acid Natural products 0.000 claims description 52
• 150000004665 fatty acids Chemical class 0.000 claims description 52
• 208000007475 hemolytic anemia Diseases 0.000 claims description 52
• 210000004369 blood Anatomy 0.000 claims description 50
• 239000008280 blood Substances 0.000 claims description 50
• 239000002775 capsule Substances 0.000 claims description 47
• 238000004820 blood count Methods 0.000 claims description 40
• 108010054147 Hemoglobins Proteins 0.000 claims description 38
• 102000001554 Hemoglobins Human genes 0.000 claims description 38
• 239000003814 drug Substances 0.000 claims description 38
• 210000001995 reticulocyte Anatomy 0.000 claims description 38
• 238000009826 distribution Methods 0.000 claims description 37
• 230000037396 body weight Effects 0.000 claims description 36
• 229940079593 drug Drugs 0.000 claims description 32
• 208000007056 sickle cell anemia Diseases 0.000 claims description 26
• 108010049003 Fibrinogen Proteins 0.000 claims description 25
• 102000008946 Fibrinogen Human genes 0.000 claims description 25
• 229940012952 fibrinogen Drugs 0.000 claims description 25
• 102100027378 Prothrombin Human genes 0.000 claims description 23
• 108010094028 Prothrombin Proteins 0.000 claims description 23
• 230000036961 partial effect Effects 0.000 claims description 23
• 229940039716 prothrombin Drugs 0.000 claims description 23
• PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 21
• 108010000499 Thromboplastin Proteins 0.000 claims description 21
• 102000002262 Thromboplastin Human genes 0.000 claims description 21
• 206010020608 Hypercoagulation Diseases 0.000 claims description 20
• 201000005665 thrombophilia Diseases 0.000 claims description 20
• 208000019501 erythrocyte disease Diseases 0.000 claims description 19
• OWFVSJHRFRIEAK-UHFFFAOYSA-N 15-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCC(O)CCCC=CC=CC=CC=CC=CC(O)=O OWFVSJHRFRIEAK-UHFFFAOYSA-N 0.000 claims description 18
• 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 14
• 201000004108 hypersplenism Diseases 0.000 claims description 14
• 239000002253 acid Substances 0.000 claims description 13
• 125000004494 ethyl ester group Chemical group 0.000 claims description 12
• 150000003839 salts Chemical group 0.000 claims description 12
• 230000007812 deficiency Effects 0.000 claims description 9
• 208000023275 Autoimmune disease Diseases 0.000 claims description 8
• 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 8
• 201000004939 Fanconi anemia Diseases 0.000 claims description 8
• 206010016880 Folate deficiency Diseases 0.000 claims description 8
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 8
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
• 206010003178 Arterial thrombosis Diseases 0.000 claims description 7
• 208000005189 Embolism Diseases 0.000 claims description 7
• 206010014522 Embolism venous Diseases 0.000 claims description 7
• 206010066476 Haematological malignancy Diseases 0.000 claims description 7
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 7
• 210000003709 heart valve Anatomy 0.000 claims description 7
• 208000015181 infectious disease Diseases 0.000 claims description 7
• 201000009225 splenic sequestration Diseases 0.000 claims description 7
• 208000004043 venous thromboembolism Diseases 0.000 claims description 7
• 208000002903 Thalassemia Diseases 0.000 claims description 6
• 208000007502 anemia Diseases 0.000 claims description 6
• 208000036654 deficiency anemia Diseases 0.000 claims description 6
• 208000009601 hereditary spherocytosis Diseases 0.000 claims description 6
• 230000009852 coagulant defect Effects 0.000 claims description 5
• 201000005787 hematologic cancer Diseases 0.000 claims description 5
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
• 150000004702 methyl esters Chemical class 0.000 claims description 4
• 208000031220 Hemophilia Diseases 0.000 claims description 3
• 208000009292 Hemophilia A Diseases 0.000 claims description 3
• 206010025323 Lymphomas Diseases 0.000 claims description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
• 208000027276 Von Willebrand disease Diseases 0.000 claims description 3
• 208000015294 blood coagulation disease Diseases 0.000 claims description 3
• 208000032839 leukemia Diseases 0.000 claims description 3
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
• 206010043554 thrombocytopenia Diseases 0.000 claims description 3
• 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims description 3
• WGDOCGARYFJEEV-UHFFFAOYSA-N 2-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=C(O)C(O)=O WGDOCGARYFJEEV-UHFFFAOYSA-N 0.000 claims 30
• 239000000902 placebo Substances 0.000 description 271
• 229940068196 placebo Drugs 0.000 description 271
• 230000009467 reduction Effects 0.000 description 200
• 238000011282 treatment Methods 0.000 description 133
• 241001465754 Metazoa Species 0.000 description 117
• 230000008859 change Effects 0.000 description 102
• 239000003981 vehicle Substances 0.000 description 97
• 238000012360 testing method Methods 0.000 description 68
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 57
• 239000000523 sample Substances 0.000 description 54
• 210000004185 liver Anatomy 0.000 description 53
• 238000004458 analytical method Methods 0.000 description 49
• 230000014509 gene expression Effects 0.000 description 46
• 206010016654 Fibrosis Diseases 0.000 description 45
• 210000003734 kidney Anatomy 0.000 description 44
• 108090000623 proteins and genes Proteins 0.000 description 44
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 43
• 108010082126 Alanine transaminase Proteins 0.000 description 43
• 230000004761 fibrosis Effects 0.000 description 41
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 39
• 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 39
• 108010035532 Collagen Proteins 0.000 description 36
• 102000008186 Collagen Human genes 0.000 description 36
• 229920001436 collagen Polymers 0.000 description 36
• 102000004169 proteins and genes Human genes 0.000 description 35
• 210000002966 serum Anatomy 0.000 description 35
• 150000002148 esters Chemical class 0.000 description 34
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 33
• 235000018102 proteins Nutrition 0.000 description 33
• 210000004027 cell Anatomy 0.000 description 32
• 210000001519 tissue Anatomy 0.000 description 32
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 31
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 31
• 241000699670 Mus sp. Species 0.000 description 29
• 238000012216 screening Methods 0.000 description 27
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
• 108700011259 MicroRNAs Proteins 0.000 description 25
• 150000002632 lipids Chemical class 0.000 description 25
• 239000002679 microRNA Substances 0.000 description 25
• DJYKWMOPVZGTRJ-PILRRHKESA-N epeleuton Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C=C/[C@@H](O)C\C=C/CC DJYKWMOPVZGTRJ-PILRRHKESA-N 0.000 description 23
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 22
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 22
• 230000000694 effects Effects 0.000 description 22
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
• 210000000056 organ Anatomy 0.000 description 22
• 230000003247 decreasing effect Effects 0.000 description 21
• 229960002591 hydroxyproline Drugs 0.000 description 21
• 238000011084 recovery Methods 0.000 description 21
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 21
• IUKXMNDGTWTNTP-OAHXIXLCSA-N 15(S)-HETrE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-OAHXIXLCSA-N 0.000 description 20
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 20
• 108010023302 HDL Cholesterol Proteins 0.000 description 20
• 238000005259 measurement Methods 0.000 description 19
• 102000005962 receptors Human genes 0.000 description 19
• 108020003175 receptors Proteins 0.000 description 19
• 230000015271 coagulation Effects 0.000 description 18
• 238000005345 coagulation Methods 0.000 description 18
• 208000024172 Cardiovascular disease Diseases 0.000 description 17
• 208000001145 Metabolic Syndrome Diseases 0.000 description 17
• 238000011887 Necropsy Methods 0.000 description 17
• 230000002526 effect on cardiovascular system Effects 0.000 description 17
• 102000009618 Transforming Growth Factors Human genes 0.000 description 16
• 108010009583 Transforming Growth Factors Proteins 0.000 description 16
• 238000009472 formulation Methods 0.000 description 16
• 230000002265 prevention Effects 0.000 description 16
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 16
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
• 238000011156 evaluation Methods 0.000 description 15
• 239000008103 glucose Substances 0.000 description 15
• 241000700159 Rattus Species 0.000 description 14
• 108010069201 VLDL Cholesterol Proteins 0.000 description 14
• 229940124301 concurrent medication Drugs 0.000 description 14
• 230000002206 pro-fibrotic effect Effects 0.000 description 14
• 230000002411 adverse Effects 0.000 description 13
• 230000036772 blood pressure Effects 0.000 description 13
• 230000002440 hepatic effect Effects 0.000 description 13
• 239000008194 pharmaceutical composition Substances 0.000 description 13
• 231100000607 toxicokinetics Toxicity 0.000 description 13
• 238000002562 urinalysis Methods 0.000 description 13
• 206010012601 diabetes mellitus Diseases 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 102000019034 Chemokines Human genes 0.000 description 11
• 108010012236 Chemokines Proteins 0.000 description 11
• 102000004877 Insulin Human genes 0.000 description 11
• 108090001061 Insulin Proteins 0.000 description 11
• 206010022489 Insulin Resistance Diseases 0.000 description 11
• 238000010241 blood sampling Methods 0.000 description 11
• 235000012000 cholesterol Nutrition 0.000 description 11
• -1 efc) Substances 0.000 description 11
• 235000021588 free fatty acids Nutrition 0.000 description 11
• 235000001727 glucose Nutrition 0.000 description 11
• 210000002216 heart Anatomy 0.000 description 11
• 229940125396 insulin Drugs 0.000 description 11
• 238000009597 pregnancy test Methods 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 238000005070 sampling Methods 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 206010008635 Cholestasis Diseases 0.000 description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
• 208000031226 Hyperlipidaemia Diseases 0.000 description 10
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 10
• 208000019425 cirrhosis of liver Diseases 0.000 description 10
• 230000034994 death Effects 0.000 description 10
• 231100000517 death Toxicity 0.000 description 10
• 230000002503 metabolic effect Effects 0.000 description 10
• 230000000717 retained effect Effects 0.000 description 10
• 230000002441 reversible effect Effects 0.000 description 10
• 238000011076 safety test Methods 0.000 description 10
• 150000003626 triacylglycerols Chemical class 0.000 description 10
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 239000000090 biomarker Substances 0.000 description 9
• 235000021152 breakfast Nutrition 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 238000010195 expression analysis Methods 0.000 description 9
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
• 230000003902 lesion Effects 0.000 description 9
• 108010076840 remnant-like particle cholesterol Proteins 0.000 description 9
• 238000001356 surgical procedure Methods 0.000 description 9
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 9
• 206010067484 Adverse reaction Diseases 0.000 description 8
• 201000001320 Atherosclerosis Diseases 0.000 description 8
• 206010015548 Euthanasia Diseases 0.000 description 8
• 206010020772 Hypertension Diseases 0.000 description 8
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 8
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 8
• 229930006000 Sucrose Natural products 0.000 description 8
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
• 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 8
• 230000006838 adverse reaction Effects 0.000 description 8
• 230000036760 body temperature Effects 0.000 description 8
• 238000013461 design Methods 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000007717 exclusion Effects 0.000 description 8
• 150000002327 glycerophospholipids Chemical class 0.000 description 8
• 230000006872 improvement Effects 0.000 description 8
• 230000002757 inflammatory effect Effects 0.000 description 8
• 208000017169 kidney disease Diseases 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 238000012545 processing Methods 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 238000007619 statistical method Methods 0.000 description 8
• 239000005720 sucrose Substances 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• 206010002091 Anaesthesia Diseases 0.000 description 7
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 7
• 208000031648 Body Weight Changes Diseases 0.000 description 7
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 7
• 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 7
• 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 7
• 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 7
• 206010072268 Drug-induced liver injury Diseases 0.000 description 7
• 108010010803 Gelatin Proteins 0.000 description 7
• 101000797332 Homo sapiens Trem-like transcript 2 protein Proteins 0.000 description 7
• 241000699666 Mus <mouse, genus> Species 0.000 description 7
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 7
• 208000030118 Red blood cell disease Diseases 0.000 description 7
• 102100032990 Trem-like transcript 2 protein Human genes 0.000 description 7
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
• 230000037005 anaesthesia Effects 0.000 description 7
• 239000003146 anticoagulant agent Substances 0.000 description 7
• 229940127219 anticoagulant drug Drugs 0.000 description 7
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
• 230000004579 body weight change Effects 0.000 description 7
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 7
• 229920000159 gelatin Polymers 0.000 description 7
• 239000008273 gelatin Substances 0.000 description 7
• 235000019322 gelatine Nutrition 0.000 description 7
• 235000011852 gelatine desserts Nutrition 0.000 description 7
• 208000019423 liver disease Diseases 0.000 description 7
• 210000004072 lung Anatomy 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 102000003390 tumor necrosis factor Human genes 0.000 description 7
• 230000002792 vascular Effects 0.000 description 7
• 102100023700 C-C motif chemokine 16 Human genes 0.000 description 6
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
• 102000004127 Cytokines Human genes 0.000 description 6
• 108090000695 Cytokines Proteins 0.000 description 6
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
• 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 6
• 208000035150 Hypercholesterolemia Diseases 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 102000004889 Interleukin-6 Human genes 0.000 description 6
• 108090001005 Interleukin-6 Proteins 0.000 description 6
• 108010028554 LDL Cholesterol Proteins 0.000 description 6
• 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 6
• 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 6
• 230000006044 T cell activation Effects 0.000 description 6
• 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 6
• 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 6
• 102100034392 Trypsin-2 Human genes 0.000 description 6
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 239000008186 active pharmaceutical agent Substances 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 210000004556 brain Anatomy 0.000 description 6
• 230000000052 comparative effect Effects 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
• 229940115449 epeleuton Drugs 0.000 description 6
• 238000011985 exploratory data analysis Methods 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 229940100601 interleukin-6 Drugs 0.000 description 6
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 6
• 229940012843 omega-3 fatty acid Drugs 0.000 description 6
• 238000003305 oral gavage Methods 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 229920002477 rna polymer Polymers 0.000 description 6
• 230000011664 signaling Effects 0.000 description 6
• 208000024891 symptom Diseases 0.000 description 6
• 230000001052 transient effect Effects 0.000 description 6
• 230000005945 translocation Effects 0.000 description 6
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 6
• 210000002700 urine Anatomy 0.000 description 6
• WLKCSMCLEKGITB-DBVSHIMFSA-N 15(S)-HEPE Chemical compound CC\C=C/C[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-DBVSHIMFSA-N 0.000 description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
• 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 description 5
• 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 5
• 206010011906 Death Diseases 0.000 description 5
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
• 102000003816 Interleukin-13 Human genes 0.000 description 5
• 108090000176 Interleukin-13 Proteins 0.000 description 5
• 102000013691 Interleukin-17 Human genes 0.000 description 5
• 108050003558 Interleukin-17 Proteins 0.000 description 5
• 102000013264 Interleukin-23 Human genes 0.000 description 5
• 108010065637 Interleukin-23 Proteins 0.000 description 5
• 102000017761 Interleukin-33 Human genes 0.000 description 5
• 108010067003 Interleukin-33 Proteins 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• 208000007536 Thrombosis Diseases 0.000 description 5
• 238000013103 analytical ultracentrifugation Methods 0.000 description 5
• 230000006907 apoptotic process Effects 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000006731 degradation reaction Methods 0.000 description 5
• 230000008021 deposition Effects 0.000 description 5
• 210000004907 gland Anatomy 0.000 description 5
• 230000002641 glycemic effect Effects 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 229940124829 interleukin-23 Drugs 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229940126601 medicinal product Drugs 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 238000004321 preservation Methods 0.000 description 5
• 238000013424 sirius red staining Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 108010088751 Albumins Proteins 0.000 description 4
• 102000009027 Albumins Human genes 0.000 description 4
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 4
• 101000848014 Homo sapiens Trypsin-2 Proteins 0.000 description 4
• 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 4
• 102000000589 Interleukin-1 Human genes 0.000 description 4
• 108010002352 Interleukin-1 Proteins 0.000 description 4
• 102000003815 Interleukin-11 Human genes 0.000 description 4
• 108090000177 Interleukin-11 Proteins 0.000 description 4
• 102000004890 Interleukin-8 Human genes 0.000 description 4
• 108090001007 Interleukin-8 Proteins 0.000 description 4
• 206010023421 Kidney fibrosis Diseases 0.000 description 4
• 206010054805 Macroangiopathy Diseases 0.000 description 4
• 102000005741 Metalloproteases Human genes 0.000 description 4
• 108010006035 Metalloproteases Proteins 0.000 description 4
• 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 4
• 239000004743 Polypropylene Substances 0.000 description 4
• 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 4
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 238000012754 cardiac puncture Methods 0.000 description 4
• 230000007211 cardiovascular event Effects 0.000 description 4
• 230000035605 chemotaxis Effects 0.000 description 4
• 230000007870 cholestasis Effects 0.000 description 4
• 231100000359 cholestasis Toxicity 0.000 description 4
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 238000010586 diagram Methods 0.000 description 4
• 235000005911 diet Nutrition 0.000 description 4
• 230000037213 diet Effects 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 229940000406 drug candidate Drugs 0.000 description 4
• 230000002500 effect on skin Effects 0.000 description 4
• 229960005135 eicosapentaenoic acid Drugs 0.000 description 4
• 238000002091 elastography Methods 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 235000019197 fats Nutrition 0.000 description 4
• 210000002950 fibroblast Anatomy 0.000 description 4
• 230000003176 fibrotic effect Effects 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 238000003304 gavage Methods 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 231100000334 hepatotoxic Toxicity 0.000 description 4
• 229940074383 interleukin-11 Drugs 0.000 description 4
• 229940096397 interleukin-8 Drugs 0.000 description 4
• XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• 229910001629 magnesium chloride Inorganic materials 0.000 description 4
• 238000004519 manufacturing process Methods 0.000 description 4
• 238000002483 medication Methods 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 239000002547 new drug Substances 0.000 description 4
• 239000012188 paraffin wax Substances 0.000 description 4
• 238000003753 real-time PCR Methods 0.000 description 4
• 238000003757 reverse transcription PCR Methods 0.000 description 4
• 208000010157 sclerosing cholangitis Diseases 0.000 description 4
• 229960002920 sorbitol Drugs 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 230000035882 stress Effects 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000003786 synthesis reaction Methods 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 238000012384 transportation and delivery Methods 0.000 description 4
• 210000000626 ureter Anatomy 0.000 description 4
• 230000035899 viability Effects 0.000 description 4
• 230000003442 weekly effect Effects 0.000 description 4
• IUKXMNDGTWTNTP-RHDCIPCHSA-N 15-HETrE Chemical compound CCCCCC(O)\C=C\C=C/C\C=C/CCCCCCC(O)=O IUKXMNDGTWTNTP-RHDCIPCHSA-N 0.000 description 3
• 230000003844 B-cell-activation Effects 0.000 description 3
• 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 3
• 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 3
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 102000011727 Caspases Human genes 0.000 description 3
• 108010076667 Caspases Proteins 0.000 description 3
• 108090000026 Caveolin 1 Proteins 0.000 description 3
• 102000003727 Caveolin 1 Human genes 0.000 description 3
• 241000725101 Clea Species 0.000 description 3
• 206010053567 Coagulopathies Diseases 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 241000233805 Phoenix Species 0.000 description 3
• YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 3
• 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 3
• 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
• 210000000577 adipose tissue Anatomy 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 238000011953 bioanalysis Methods 0.000 description 3
• 210000001185 bone marrow Anatomy 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• PNDKCRDVVKJPKG-WHERJAGFSA-N cenicriviroc Chemical compound C1=CC(OCCOCCCC)=CC=C1C1=CC=C(N(CC(C)C)CCC\C(=C/2)C(=O)NC=3C=CC(=CC=3)[S@@](=O)CC=3N(C=NC=3)CCC)C\2=C1 PNDKCRDVVKJPKG-WHERJAGFSA-N 0.000 description 3
• 229950011033 cenicriviroc Drugs 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 208000020832 chronic kidney disease Diseases 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000012790 confirmation Methods 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 238000001647 drug administration Methods 0.000 description 3
• JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
• 235000004626 essential fatty acids Nutrition 0.000 description 3
• 239000012634 fragment Substances 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• 208000018706 hematopoietic system disease Diseases 0.000 description 3
• 230000003082 hepatotoxic effect Effects 0.000 description 3
• 230000003284 homeostatic effect Effects 0.000 description 3
• 201000001421 hyperglycemia Diseases 0.000 description 3
• 229960004716 idoxuridine Drugs 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000004068 intracellular signaling Effects 0.000 description 3
• 229960002725 isoflurane Drugs 0.000 description 3
• 230000000512 lipotoxic effect Effects 0.000 description 3
• 238000012317 liver biopsy Methods 0.000 description 3
• 230000004807 localization Effects 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 231100000682 maximum tolerated dose Toxicity 0.000 description 3
• 210000003205 muscle Anatomy 0.000 description 3
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 235000021590 normal diet Nutrition 0.000 description 3
• 229910052760 oxygen Inorganic materials 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• 230000037081 physical activity Effects 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 210000000952 spleen Anatomy 0.000 description 3
• 238000000528 statistical test Methods 0.000 description 3
• 230000007863 steatosis Effects 0.000 description 3
• 231100000240 steatosis hepatitis Toxicity 0.000 description 3
• 210000004500 stellate cell Anatomy 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000014616 translation Effects 0.000 description 3
• 231100000402 unacceptable toxicity Toxicity 0.000 description 3
• 210000003462 vein Anatomy 0.000 description 3
• 238000012795 verification Methods 0.000 description 3
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
• WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 description 2
• 102100040881 60S acidic ribosomal protein P0 Human genes 0.000 description 2
• 101150020966 Acta2 gene Proteins 0.000 description 2
• 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 2
• 101710192004 Actin, aortic smooth muscle Proteins 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
• 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 2
• 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 101710199744 Anionic trypsin-2 Proteins 0.000 description 2
• 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
• 208000035404 Autolysis Diseases 0.000 description 2
• 102000051485 Bcl-2 family Human genes 0.000 description 2
• 108700038897 Bcl-2 family Proteins 0.000 description 2
• 239000011547 Bouin solution Substances 0.000 description 2
• 108010074051 C-Reactive Protein Proteins 0.000 description 2
• 102100032752 C-reactive protein Human genes 0.000 description 2
• 101150072801 COL1A2 gene Proteins 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 206010057248 Cell death Diseases 0.000 description 2
• ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
• 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 2
• 102000004420 Creatine Kinase Human genes 0.000 description 2
• 108010042126 Creatine kinase Proteins 0.000 description 2
• 206010064769 Dactylitis Diseases 0.000 description 2
• 206010052337 Diastolic dysfunction Diseases 0.000 description 2
• 238000008789 Direct Bilirubin Methods 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 208000032928 Dyslipidaemia Diseases 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 102000001301 EGF receptor Human genes 0.000 description 2
• 108060006698 EGF receptor Proteins 0.000 description 2
• 102100023795 Elafin Human genes 0.000 description 2
• 108010015972 Elafin Proteins 0.000 description 2
• 206010048554 Endothelial dysfunction Diseases 0.000 description 2
• 206010015719 Exsanguination Diseases 0.000 description 2
• 238000001134 F-test Methods 0.000 description 2
• 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 description 2
• 206010059183 Familial hypertriglyceridaemia Diseases 0.000 description 2
• 206010017577 Gait disturbance Diseases 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• 208000002705 Glucose Intolerance Diseases 0.000 description 2
• 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
• 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
• 108010010234 HDL Lipoproteins Proteins 0.000 description 2
• 102000015779 HDL Lipoproteins Human genes 0.000 description 2
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 206010018910 Haemolysis Diseases 0.000 description 2
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
• 101000673456 Homo sapiens 60S acidic ribosomal protein P0 Proteins 0.000 description 2
• 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 2
• 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 2
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
• 206010056997 Impaired fasting glucose Diseases 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
• 238000012313 Kruskal-Wallis test Methods 0.000 description 2
• 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
• 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
• 238000001295 Levene's test Methods 0.000 description 2
• 208000017170 Lipid metabolism disease Diseases 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 101100286247 Mus musculus Id1 gene Proteins 0.000 description 2
• 229910002651 NO3 Inorganic materials 0.000 description 2
• 241000772415 Neovison vison Species 0.000 description 2
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 208000018262 Peripheral vascular disease Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 101710151381 Serine protease 2 Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 238000000692 Student's t-test Methods 0.000 description 2
• 244000269722 Thea sinensis Species 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 102000003929 Transaminases Human genes 0.000 description 2
• 108090000340 Transaminases Proteins 0.000 description 2
• 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 2
• 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 2
• 206010060755 Type V hyperlipidaemia Diseases 0.000 description 2
• 230000003187 abdominal effect Effects 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 125000005907 alkyl ester group Chemical group 0.000 description 2
• JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
• 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
• 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
• DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 230000003078 antioxidant effect Effects 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 208000035707 autosomal dominant type B hypercholesterolemia Diseases 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 108010079292 betaglycan Proteins 0.000 description 2
• 229960001948 caffeine Drugs 0.000 description 2
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
• 239000004202 carbamide Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 210000004323 caveolae Anatomy 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 210000003679 cervix uteri Anatomy 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 235000017471 coenzyme Q10 Nutrition 0.000 description 2
• ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
• 230000037319 collagen production Effects 0.000 description 2
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
• 210000001953 common bile duct Anatomy 0.000 description 2
• 238000011109 contamination Methods 0.000 description 2
• 239000003433 contraceptive agent Substances 0.000 description 2
• 229940124558 contraceptive agent Drugs 0.000 description 2
• 208000026758 coronary atherosclerosis Diseases 0.000 description 2
• 229940109239 creatinine Drugs 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000013480 data collection Methods 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
• 238000002298 density-gradient ultracentrifugation Methods 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 235000015872 dietary supplement Nutrition 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 2
• 230000008694 endothelial dysfunction Effects 0.000 description 2
• 230000008753 endothelial function Effects 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 201000001386 familial hypercholesterolemia Diseases 0.000 description 2
• 201000005577 familial hyperlipidemia Diseases 0.000 description 2
• 230000003352 fibrogenic effect Effects 0.000 description 2
• 239000000834 fixative Substances 0.000 description 2
• 230000004190 glucose uptake Effects 0.000 description 2
• 230000005484 gravity Effects 0.000 description 2
• 235000009569 green tea Nutrition 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 238000005534 hematocrit Methods 0.000 description 2
• 230000008588 hemolysis Effects 0.000 description 2
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 229920002674 hyaluronan Polymers 0.000 description 2
• 229960003160 hyaluronic acid Drugs 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
• 201000008980 hyperinsulinism Diseases 0.000 description 2
• 208000000522 hyperlipoproteinemia type IV Diseases 0.000 description 2
• 208000006575 hypertriglyceridemia Diseases 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 210000000936 intestine Anatomy 0.000 description 2
• 230000000302 ischemic effect Effects 0.000 description 2
• 150000002576 ketones Chemical class 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• 108010000849 leukocyte esterase Proteins 0.000 description 2
• 201000002818 limb ischemia Diseases 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 238000007431 microscopic evaluation Methods 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 235000020925 non fasting Nutrition 0.000 description 2
• 150000005830 nonesterified fatty acids Chemical class 0.000 description 2
• 230000001473 noxious effect Effects 0.000 description 2
• 239000006014 omega-3 oil Substances 0.000 description 2
• 229940033080 omega-6 fatty acid Drugs 0.000 description 2
• 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
• 210000001328 optic nerve Anatomy 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 210000004303 peritoneum Anatomy 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 230000007505 plaque formation Effects 0.000 description 2
• 239000004014 plasticizer Substances 0.000 description 2
• 229920001155 polypropylene Polymers 0.000 description 2
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
• 201000009104 prediabetes syndrome Diseases 0.000 description 2
• 230000009862 primary prevention Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 239000003161 ribonuclease inhibitor Substances 0.000 description 2
• 230000009863 secondary prevention Effects 0.000 description 2
• 230000028043 self proteolysis Effects 0.000 description 2
• 208000013220 shortness of breath Diseases 0.000 description 2
• 231100000161 signs of toxicity Toxicity 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 239000002904 solvent Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 210000001562 sternum Anatomy 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 238000012353 t test Methods 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 210000000115 thoracic cavity Anatomy 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• 235000021476 total parenteral nutrition Nutrition 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 125000005457 triglyceride group Chemical group 0.000 description 2
• 210000000689 upper leg Anatomy 0.000 description 2
• OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
• 239000004034 viscosity adjusting agent Substances 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical class 0.000 description 1
• 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
• KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• 229940084778 1,4-sorbitan Drugs 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• WLKCSMCLEKGITB-MXTKCVSJSA-N 15(R)-HEPE Chemical compound CC\C=C/C[C@@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-MXTKCVSJSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
• 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• 101800000240 Allatostatin-5 Proteins 0.000 description 1
• 240000004178 Anthoxanthum odoratum Species 0.000 description 1
• 108010071619 Apolipoproteins Proteins 0.000 description 1
• 102000007592 Apolipoproteins Human genes 0.000 description 1
• 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 1
• 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• 206010004593 Bile duct cancer Diseases 0.000 description 1
• 206010056375 Bile duct obstruction Diseases 0.000 description 1
• 206010004637 Bile duct stone Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 241001474374 Blennius Species 0.000 description 1
• 241000566113 Branta sandvicensis Species 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• 102000000905 Cadherin Human genes 0.000 description 1
• 108050007957 Cadherin Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 201000009331 Choledocholithiasis Diseases 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 102000001187 Collagen Type III Human genes 0.000 description 1
• 108010069502 Collagen Type III Proteins 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 206010011985 Decubitus ulcer Diseases 0.000 description 1
• 208000027219 Deficiency disease Diseases 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 235000009414 Elaeocarpus kirtonii Nutrition 0.000 description 1
• 208000000624 Esophageal and Gastric Varices Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• 102000016359 Fibronectins Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 241001284615 Frangula californica Species 0.000 description 1
• OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 1
• 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
• WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
• 108010001517 Galectin 3 Proteins 0.000 description 1
• 102100039558 Galectin-3 Human genes 0.000 description 1
• 102000007563 Galectins Human genes 0.000 description 1
• 108010046569 Galectins Proteins 0.000 description 1
• 208000009139 Gilbert Disease Diseases 0.000 description 1
• 208000022412 Gilbert syndrome Diseases 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
• 208000034706 Graft dysfunction Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 241000506654 Haemulon album Species 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 206010019708 Hepatic steatosis Diseases 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
• 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
• JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
• 238000000585 Mann–Whitney U test Methods 0.000 description 1
• 239000012901 Milli-Q water Substances 0.000 description 1
• 208000000996 Mirizzi syndrome Diseases 0.000 description 1
• 239000004368 Modified starch Substances 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 101100021482 Mus musculus Lnpk gene Proteins 0.000 description 1
• 108050000637 N-cadherin Proteins 0.000 description 1
• SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
• IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
• 206010067482 No adverse event Diseases 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010058667 Oral toxicity Diseases 0.000 description 1
• 101100497331 Oryza sativa subsp. japonica CRL5 gene Proteins 0.000 description 1
• 235000021314 Palmitic acid Nutrition 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• MFLCLMHBOLWTHH-UHFFFAOYSA-N Panial Natural products COc1ccc2C=CC(=O)Oc2c1C(O)C=C(/C)C=O MFLCLMHBOLWTHH-UHFFFAOYSA-N 0.000 description 1
• 239000005662 Paraffin oil Substances 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 201000002150 Progressive familial intrahepatic cholestasis Diseases 0.000 description 1
• QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 244000294611 Punica granatum Species 0.000 description 1
• 235000014360 Punica granatum Nutrition 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 235000004433 Simmondsia californica Nutrition 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 244000236151 Tabebuia pallida Species 0.000 description 1
• 235000013584 Tabebuia pallida Nutrition 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
• 108050003222 Transferrin receptor protein 1 Proteins 0.000 description 1
• BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
• 208000004608 Ureteral Obstruction Diseases 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 206010056091 Varices oesophageal Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• YBLSOPCYTIDHFU-UHFFFAOYSA-J [Na+].[Cl-].[K+].[Ca+2].[O-]P([O-])([O-])=O Chemical compound [Na+].[Cl-].[K+].[Ca+2].[O-]P([O-])([O-])=O YBLSOPCYTIDHFU-UHFFFAOYSA-J 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 230000004308 accommodation Effects 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 238000005903 acid hydrolysis reaction Methods 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 239000000538 analytical sample Substances 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000002429 anti-coagulating effect Effects 0.000 description 1
• 230000003178 anti-diabetic effect Effects 0.000 description 1
• 230000002785 anti-thrombosis Effects 0.000 description 1
• 239000003472 antidiabetic agent Substances 0.000 description 1
• 210000000709 aorta Anatomy 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 229940000031 blood and blood forming organ drug Drugs 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 231100001015 blood dyscrasias Toxicity 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 229930003827 cannabinoid Natural products 0.000 description 1
• 239000003557 cannabinoid Substances 0.000 description 1
• 229940065144 cannabinoids Drugs 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
• 150000001765 catechin Chemical class 0.000 description 1
• 235000005487 catechin Nutrition 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 210000004534 cecum Anatomy 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 239000007910 chewable tablet Substances 0.000 description 1
• 230000001055 chewing effect Effects 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 150000001840 cholesterol esters Chemical class 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 230000007665 chronic toxicity Effects 0.000 description 1
• 231100000160 chronic toxicity Toxicity 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229960003920 cocaine Drugs 0.000 description 1
• 239000003026 cod liver oil Substances 0.000 description 1
• 235000012716 cod liver oil Nutrition 0.000 description 1
• 229940110767 coenzyme Q10 Drugs 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229920002770 condensed tannin Polymers 0.000 description 1
• 238000004624 confocal microscopy Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
• 238000011157 data evaluation Methods 0.000 description 1
• 238000013523 data management Methods 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 230000035487 diastolic blood pressure Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 235000019800 disodium phosphate Nutrition 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
• KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• 238000002565 electrocardiography Methods 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 201000000523 end stage renal failure Diseases 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 210000000918 epididymis Anatomy 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 208000024170 esophageal varices Diseases 0.000 description 1
• 201000010120 esophageal varix Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 208000010706 fatty liver disease Diseases 0.000 description 1
• JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
• KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
• 229940114124 ferulic acid Drugs 0.000 description 1
• 235000001785 ferulic acid Nutrition 0.000 description 1
• KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000012631 food intake Nutrition 0.000 description 1
• 230000037406 food intake Effects 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 238000003633 gene expression assay Methods 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000014101 glucose homeostasis Effects 0.000 description 1
• 125000005456 glyceride group Chemical class 0.000 description 1
• 125000003732 glycerophospholipid group Chemical group 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 229940087559 grape seed Drugs 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 230000002949 hemolytic effect Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 231100000753 hepatic injury Toxicity 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 208000002672 hepatitis B Diseases 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 230000000423 heterosexual effect Effects 0.000 description 1
• 238000007489 histopathology method Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229960004135 idebenone Drugs 0.000 description 1
• JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 230000003601 intercostal effect Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 210000004731 jugular vein Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 229960004488 linolenic acid Drugs 0.000 description 1
• 230000006372 lipid accumulation Effects 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 239000008263 liquid aerosol Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 229940057995 liquid paraffin Drugs 0.000 description 1
• 230000005976 liver dysfunction Effects 0.000 description 1
• 208000018191 liver inflammation Diseases 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 235000012661 lycopene Nutrition 0.000 description 1
• 229960004999 lycopene Drugs 0.000 description 1
• OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
• 239000001751 lycopene Substances 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 238000013227 male C57BL/6J mice Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 description 1
• 238000013160 medical therapy Methods 0.000 description 1
• 229940057917 medium chain triglycerides Drugs 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000002284 membrane microdomain Anatomy 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 238000002705 metabolomic analysis Methods 0.000 description 1
• 230000001431 metabolomic effect Effects 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 239000002637 mydriatic agent Substances 0.000 description 1
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229960003966 nicotinamide Drugs 0.000 description 1
• 235000005152 nicotinamide Nutrition 0.000 description 1
• 239000011570 nicotinamide Substances 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 150000002826 nitrites Chemical class 0.000 description 1
• 230000005937 nuclear translocation Effects 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 230000009965 odorless effect Effects 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 231100000418 oral toxicity Toxicity 0.000 description 1
• 235000015205 orange juice Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 229960002275 pentobarbital sodium Drugs 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000000447 pesticide residue Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 150000003906 phosphoinositides Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 235000018192 pine bark supplement Nutrition 0.000 description 1
• 238000013439 planning Methods 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 150000008442 polyphenolic compounds Chemical class 0.000 description 1
• 235000013824 polyphenols Nutrition 0.000 description 1
• 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
• 230000005195 poor health Effects 0.000 description 1
• 208000007232 portal hypertension Diseases 0.000 description 1
• 231100000683 possible toxicity Toxicity 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
• 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 229940106796 pycnogenol Drugs 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 238000012950 reanalysis Methods 0.000 description 1
• NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 235000021283 resveratrol Nutrition 0.000 description 1
• 229940016667 resveratrol Drugs 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
• 235000017700 silymarin Nutrition 0.000 description 1
• 229960004245 silymarin Drugs 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000000934 spermatocidal agent Substances 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 238000013223 sprague-dawley female rat Methods 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000012066 statistical methodology Methods 0.000 description 1
• JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 201000009032 substance abuse Diseases 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 229960005196 titanium dioxide Drugs 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
• QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
• ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 229960004791 tropicamide Drugs 0.000 description 1
• DYNZICQDCVYXFW-AHZSKCOESA-N trovafloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F DYNZICQDCVYXFW-AHZSKCOESA-N 0.000 description 1
• 229940055820 trovan Drugs 0.000 description 1
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
• 229940035936 ubiquinone Drugs 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 238000000825 ultraviolet detection Methods 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 238000009423 ventilation Methods 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 238000009528 vital sign measurement Methods 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1